Several years ago, Microsoft cofounder Bill Gates asked a simple question: Were enough of the world's brightest minds in science and technology directed at solving the daunting health problems of developing nations? Finding that the answer was no, the Bill & Melinda Gates Foundation set out to engage the scientific research community with a new funding initiative called the Grand Challenges in Global Health.
In 2003, an illustrious international scientific advisory board identified a set of crucial scientific problems that must be solved in order to make real progress in preventing and treating diseases that kill millions of people every year in the developing world. These 14 Grand Challenges include developing vaccines that do not require refrigeration, designing antigens to provoke protective immunity, finding ways to control insect vectors of disease, inventing therapies to cure latent infections, and creating new health-assessment tools for regions lacking reliable recordkeeping or sophisticated laboratories.
Last summer, after a long, rigorous, and highly competitive selection process, the Grand Challenges program awarded $436.6 million to 43 innovative research projects, to be carried out by investigators in 33 countries. The endeavor "is a great opportunity to allow people to think a little bit out of the box about some problems that are incredibly hard," says Carol Dahl, director of global health technologies at the Gates Foundation in Seattle. The initiative is financed with a total of $450 million from the Foundation, $27.1 million from the Wellcome Trust, and $4.5 million from the Canadian Institutes of Health Research.
The Grand Challenges effort is one of the most ambitious projects launched by the Gates Foundation to date. Since its inception in 1998, the charity has pledged more than $6 billion to improving global health. This new source of funding has dramatically pumped life-and optimism-into the long-parched landscape of research and development into diseases that primarily afflict the developing world, such as AIDS, malaria, and tuberculosis as well as neglected tropical illnesses such as hookworm, schistosomiasis, and Chagas disease.
Sponsoring research as well as disease prevention and treatment efforts, the Foundation has dedicated $1.1 billion to fighting AIDS/HIV, $640 million to combating malaria, and $900 million to tuberculosis. It has poured another $1.5 billion into the Global Alliance for Vaccines and Immunization (GAVI), a Geneva-based coalition that has delivered traditional and new vaccines to roughly 130 million youngsters-saving an estimated 1.7 million lives in more than 70 countries. Catalyzed by the Gates' largess, other nonprofit organizations and government agencies have joined the cause. Bill Gates has "made global health sexy," says tropical diseases researcher Peter Hotez of George Washington University in Washington, DC, who is working on a vaccine to combat hookworm.
Betting on Science
The Grand Challenges program epitomizes the Gates Foundation's support of high-risk and large-scale research proposals that are unlikely to receive traditional kinds of funding. For example, molecular biologist Anthony James at the University of California, Irvine and his collaborators (from eight other universities and one biotechnology firm) are engineering transgenic mosquitoes with a $19.7 million grant, one of several funded approaches to Grand Challenge #7, which aims to prevent insect vectors from transmitting infectious diseases.
The mosquito species they are studying is Aedes aegypti. This insect transmits a potentially fatal tropical pathogen called dengue virus that infects 50 to 100 million people each year worldwide and has caused serious epidemics in South-East Asia, islands of the Western Pacific, and South America. James, arbovirologist Kenneth Olson of Colorado State University, and their colleagues are engineering Aedes to express a synthetic gene construct that results in destruction of the dengue virus genome. Although still far off, the ultimate goal is to release the transgenic insects into the wild, enabling the gene to move through the native mosquito population and thus helping to break the disease transmission cycle.
The core of the synthetic construct encodes a double-stranded RNAdesigned by Olson's lab-formed by the sense and antisense sequences of a segment from the RNA genome of dengue virus serotype 2. When the double-stranded RNA is expressed in cells of the mosquito midgut, an innate immune response called RNA interference (RNAi) is activated that chops up the RNA genome of dengue virus ingested in an infected blood meal. In lab studies, the strategy appears to work, James says. Transgenic mosquitoes challenged with a dengue virus-infected blood meal exhibit only very low titers of the pathogen.
The major hurdle now is finding a way to drive the synthetic gene through a wild-type mosquito popula-
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The Gates Foundation is funding high-risk research into new ways to improve health in developing countries, but ensuring that the fruits of these studies reach the people who need them most may be the biggest challenge of all.
tion. The consortium is testing several methods. James' group is hitching the anti-dengue virus construct to a DNA element called a transposon that can move through the mosquito genome, potentially replicating itself many times with each reproductive cycle. To express the transposable elements in the mosquito germline (so that all generations of progeny carry the accompanying anti-dengue construct), and to prevent this genetic weapon from spreading into nontarget organisms, the scientists have linked a transposon called Mos1 to a species-specific mosquito promoter of nanos, a developmentally regulated insect gene. The transposition is activated in the mosquito embryo during early development, but only at one polewhere future egg and sperm will form. Putting it all together, the researchers are now transforming mosquitoes with the entire transposon-plus-anti-dengue construct and analyzing whether the "gene drive" is effective.
Within 5 years, the research consortium hopes to take several varieties of their transgenic, dengue virusfighting mosquitoes into greenhouse field studies in a tropical country where dengue fever is endemic. The National Institutes of Health (NIH) does not fund such ambitious benchto-field projects, James says. Only Gates is "willing to take the gamble." For the first time, a lack of resources isn't a barrier, he says.
Tapping Nature's Defenses Another Grand Challenges goal is to surmount the major difficulty of delivering viable vaccines to people in the developing world where a break in the "cold chain" of refrigerators and cold boxes may lead to inactivation of vaccines. Abraham L. Sonenshein, a molecular geneticist at the Tufts University School of Medicine in Boston, has come up with one possible solution. He is using a $5 million award to engineer a vaccine that is packaged in heat-resistant bacterial spores. Impervious to heat, cold, radiation, antibiotics, and low pH, "bacterial spores are just about the most resistant biological entities that we know, " he says.
Sonenshein and his collaborators are splicing vaccine antigens for diphtheria, pertussis, and tetanus into the genome of Bacillus subtilis so that the innocuous soil bacterium displays those proteins on its surface in its replicative phase or its spore phase, or both. The genetically engineered spores could be freeze-dried and stored in aluminum packets for years at any temperature. When needed, the spore vaccine could be mixed with water and given to people as a drink. In theory, following ingestion, some spores would adhere to the intestinal tract and would germinate, releasing bacteria capable of replication. The primary hurdle, says Sonenshein, will be to ensure that enough antigen is presented to intestinal cells to trigger a sufficiently strong immune response that creates protective immunity. Sonenshein and his colleagues are also working on a spore vaccine for rotavirus, a diarrheal infection that kills roughly 500,000 children worldwide each year. They hope to take their experimental vaccines into human clinical trials within 5 years. Meanwhile, another Grand Challenges team is using a $19 million grant to characterize the molecular basis of innate immunity against malaria, which kills more than 1 million people annually, most of them children in Africa. Young children who survive multiple infections of the malaria parasite Plasmodium falciparum seem to acquire natural resistance to severe forms of the disease. A group led by Army physician Patrick Duffy, a researcher at the Seattle Biomedical Research Institute, will screen blood samples from 14,000 babies, young children, and adults in Tanzania to determine whether specific phenotypes of the P. falciparum parasite are responsible for severe childhood malaria.
Using mass spectrometry and microarray analysis, the investigators will search for any unique parasite proteins that provoke an antibody response and then will examine whether individuals producing those antibodies are less susceptible to severe illness or death. "Once you know what protective immunity is, it provides a very economical pathway to determining what are the proteins that should be put into a vaccine," says Duffy.
From Lab Research to Field Reality
To maximize the odds of achieving their research goals, principal investigators of Grand Challenges projects are required to stipulate milestones and timelines for their work. For-profit grantees are used to such planning exercises, but the academics found it "a little bit more challenging," says Daniel Carucci, director of the Grand Challenges in Global Health at the Foundation of the NIH (FNIH). (The FNIH, an independent public charity that administers private grants to support NIH programs or other complementary research, is managing 21 Grand Challenges awards.)
The grantees also must be prepared to ensure that any medicines or other health tools created with Grand Challenges money will be available at affordable prices to developing nations. The program "is definitely not about generating new knowledge in and of itself-it's about solving problems," says Carucci. In a "global access strategy," principal investigators are required to outline intellectual property ownership issues, licensing strategies, and potential commercial partners. Scientists can patent their work, but if they fail to make their inventions accessible to poor countries, their award contracts include fallback provisions, such as requiring the grantee to give the FNIH a license to fulfill the charitable mission, says Carucci.
Some public health experts have criticized the Grand Challenges initiative for investing too heavily in speculative high-tech ideas. They say the funds could be used to help save more lives today by distributing existing medicines or helping to build clean water and sanitation systems or combating malnutrition. But others say that current treatments aren't enough, pointing to malaria's resurgence in recent decades because resistance to insecticides has developed in the mosquito vector that transmits the malaria parasite. "You Cell 124, February 24, 2006 ©2006 Elsevier Inc. 663 need to use existing control tools that you have at hand, and be able to fold in the new ones over time," says Hotez at George Washington University.
Although some Gates grants do support health systems and infrastructure, the charity's general view is that governments bear primary responsibility for improvements in those areas. But Regina Rabinovich, the Gates Foundation's director of infectious diseases, acknowledges that the world's overall funding pie needs to grow to cover both basic health needs and future interventions. "It doesn't help to develop new drugs, vaccines or diagnostics if you can't use them," Rabinovich says.
In fact, assessments of the Gatesfunded immunization campaign, GAVI, have underscored to global health experts the importance of investing in the health systems of developing countries. The vaccine alliance's experience holds significant implications for other global health initiatives, including the Grand Challenges program. This is due to the fact that new vaccines or medical treatments might eventually be distributed to developing countries through the GAVI system or through similar public-private partnerships.
Getting Vaccines to the Needy
Launched in 2000 with $750 million of Gates seed money, GAVI rapidly provided 5-year grants to the neediest countries to purchase (through UNICEF) and deliver new and underused childhood vaccines. The innovative public-private partnership includes UNICEF, the World Health Organization (WHO), vaccine makers, and governments of many industrialized nations that also contributed millions to the mission.
With GAVI funds, countries have vaccinated 90 million children against hepatitis B; 14 million against Haemophilus influenza type b (Hib), a major cause of meningitis and pneumonia; and 14 million against yellow fever. And basic vaccines against diphtheria, pertussis, and tetanus have reached 13 million extra youngsters. Thanks to GAVI and the Gates Foundation, "it's really a huge breakthrough that we are working toward a vision of the kids in poor countries having access to the same vaccines that my kids get," says Ruth Levine, a health financing expert at the Center for Global Development (CGD) in Washington, DC.
Despite these successes, analyses show the alliance has encountered some major difficulties on the ground. One study (funded by Save the Children UK) found that immunization efforts in developing countries were hindered by a shortage of some vaccines and by deep-seated weaknesses in health care infrastructure. These deficiencies included shortages of staff workers and transport vehicles, unreliable health information systems, and breakdowns in the vaccine cold chain.
In his book Crusade to Immunize the World's Children, William Muraskin, a social historian at Queens College of the City University of New York, says the coalition imposed a vaccine-focused agenda on the health ministries of poor nations that didn't pay sufficient attention to their most urgent disease-fighting priorities. And although the alliance predicted that by the end of 5 years vaccine prices would drop and countries would be able to take over the costs of the hepatitis B and Hib vaccines-which in some cases doubled or tripled national immunization expenses-neither happened, says CGD's Levine. Given the situation, Muraskin questions how GAVI will succeed in its plans to introduce even pricier vaccines against rotavirus and pneumonia, or future vaccines against malaria, HIV, and TB.
Jean-Marie Okwo-Bele, WHO's director of immunization, vaccines, and biologicals and a former health official in the Democratic Republic of Congo, says that GAVI "has been successful on several fronts, and like any other thing, it also has some areas that need improvements." He agrees that the coalition went in with "a bit too much of a top-down approach," but it recently set up sound processes for receiving more input from the health ministries of developing countries. "GAVI is certainly taking the lessons forward," Okwo-Bele says.
For instance, GAVI is providing a second phase of financing to countries over a longer, 10 year term, with recipients paying a gradually increasing share of vaccine costs. It is also offering more funding to shore up basic health services at the district level, says GAVI executive secretary Julian Lob-Levyt. The Gates Foundation has demonstrated its continuing support with another $750 million award, and even more importantly, six nations have agreed to set up a financing mechanism that will raise $4 billion over a decade. As for sustainability, deciding to deny the world's poorest people the benefits of health because their nations will never have enough money to pay for new medicines is "not acceptable," says Lob-Levyt. "We have to be much more ambitious."
Other Gates grantees are watching GAVI closely. At the Malaria Vaccine Initiative in Seattle, director Melinda Moree and associates have begun laying the groundwork to avoid similar problems when they bring a malaria vaccine to market, hopefully within the next decade. What worries Moree most isn't failure to create an effective treatment-it's inventing one that nobody could afford or get access to. "That would be the worst outcome," she says.
As the Gates Foundation's Rabinovich puts it, success is not defined as licensing a new drug; it is measured by actual impact on people's health. Ultimately, one of the biggest challenges is guaranteeing that any medical solutions designed for poor countries-whether through the Grand Challenges program or any other global health initiative-reach those who need them most.
